How can we move beyond endocrine therapy in HR+/HER2- breast cancer?

22 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses the potential of immunotherapy in the hormone receptor-positive breast cancer space, highlighting that while this subtype is generally considered immunologically cold, a subset of patients may benefit from immune checkpoint inhibitors. Combination therapies, such as immune checkpoint inhibitors with chemotherapy in the neoadjuvant setting or with endocrine therapy and CDK4/6 inhibitors in the metastatic setting, may help overcome estrogen-driven immune suppression. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo